IP waiver won’t solve vaccine problems, warn experts

A landmark proposal to suspend provisions of TRIPS for COVID-19 vaccines and treatments was first raised in October 2020. But, nearly a year and a half later, in January 2022, it seems there is no end in sight, with members of the World Trade Organization (WTO) failing to reach consensus.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Chinese biotech strikes billion dollar deal in nextgen cancer race

20 January 2026 Magic Circle and major US firm among dealmakers who worked on the licensing agreement for a bispecific antibody candidate, marking another significant outbound licensing deal from China’s biopharma sector.

Americas

$5.4bn medtech leader fails to bury a rival's patent

19 January 2026 An Israeli medical device company’s lawsuit claims Edwards knowingly infringed its heart-valve patent, raising new risks as the giant pursues growth beyond its core market.

Careers

Senior four-partner team leaves A&O Shearman

16 January 2026 The team, known for pharmaceutical and biotechnology patent litigation—including Hatch-Waxman and BPCIA disputes—as well as trade secret and licensing matters, joins a rival US firm.

More features

Chinese biotech strikes billion dollar deal in nextgen cancer race

$5.4bn medtech leader fails to bury a rival's patent

Senior four-partner team leaves A&O Shearman

Final call: Who are the world’s best in-house counsel?

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Italian medtech startup beats larger US rival in UPC dispute

Senior USPTO solicitor steps into private practice

IP waiver won’t solve vaccine problems, warn experts

More on this story

Editor's picks

Editor's picks

More features